BRONXIAL ASTMAGA KASALLIGIGA ZAMONAVIY YONDASHUV
Keywords:
Kalit so'zlar:Bronxial astma, zamonaviy yondashuvlar, diagnostika, davolash, profilaktika, nazorat, patofiziologiya, farmakologiya, nofarmakologiya.Abstract
Annotatsiya:Ushbu maqolada bronxial astmaga zamonaviy yondashuvlar,
diagnostika usullari, davolash strategiyalari va profilaktika choralari atroflicha
o'rganiladi. Maqola bronxial astma bilan og'rigan bemorlarning hayot sifatini
yaxshilashga qaratilgan so'nggi ilmiy yutuqlar va klinik tavsiyalarga e'tibor qaratadi.
Unda kasallikning patofiziologiyasi, genetik va ekologik omillarning ta'siri,
shuningdek, individual davolash rejalarini ishlab chiqishda qo'llaniladigan
farmakologik va nofarmakologik usullar ko'rib chiqiladi. Maqolada shuningdek, astma
nazorati, bemorlarni o'qitish va kasallikning uzoq muddatli boshqaruvi muhimligi
ta'kidlanadi.
References
Adabiyotlar ro'yxati
1. World Health Organization. Asthma. (2023). https://www.who.int/news-room/fact-
sheets/detail/asthma
2. Global Initiative for Asthma. Global Strategy for Asthma Management and
Prevention. (2024). https://ginasthma.org/
3. Barnes PJ. Pathophysiology of asthma. Br J Pharmacol. 2011;163(Suppl 1):S9-
S12.
4. Agache I, Akdis CA. Precision medicine in allergic diseases. J Allergy Clin
Immunol. 2018;141(1):28-39.
5. Holgate ST. The airway epithelium as a target for asthma therapy. Proc Am Thorac
Soc. 2011;8(1):50-55.
6. Ober C, Yao L. The genetics of asthma and allergic disease. J Allergy Clin Immunol.
2011;127(3):667-670.
7. Salo PM, et al. Prevalence of childhood asthma and wheezing in the US. Pediatrics.
2018;141(3):e20173255.
8. Global Initiative for Asthma. GINA Report. (2024). https://ginasthma.org/gina-
report-global-strategy-for-asthma-management-and-prevention/
9. Busse WW, et al. Biologics in asthma: current status and future prospects. Ann
Allergy Asthma Immunol. 2016;117(3):214-222.
10. Pellegrino R, et al. Interpretative strategies for lung function tests. Eur Respir J.
2005;26(5):948-968.
11. Miller MR, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
12. Homburger HA, et al. Serum total IgE and specific IgE in relation to allergic
diseases. J Allergy Clin Immunol. 1989;84(1):23-29.
13. Barnes PJ. Inhaled corticosteroids in asthma. Am J Respir Crit Care Med.
2006;173(1):151-162.
14. Peters SP, et al. Inhaled corticosteroids and long-acting beta2-agonists: safety and
efficacy. J Allergy Clin Immunol. 2013;131(5):1257-1264.
15. Humbert M, et al. Omalizumab in severe allergic asthma: an update. Allergy.
2014;69(1):1-10.
16. Pelaia G, et al. Mepolizumab and reslizumab: anti-IL-5 monoclonal antibodies for
the treatment of severe eosinophilic asthma. Expert Rev Clin Immunol.
2017;13(4):379-389.
17. FitzGerald JM, et al. Benralizumab, an anti-interleukin-5 receptor alpha
monoclonal antibody, as add-on treatment for severe eosinophilic asthma. Lancet.
2016;388(10056):2128-2141.
18. Platts-Mills TAE. Allergen avoidance in the treatment of asthma and allergic
rhinitis. N Engl J Med. 2004;351(13):1333-1341.
19. Gibson PG, et al. Self-management education for adults with asthma. Cochrane
Database Syst Rev. 2002;(3):CD000088.
20. Al-Azzawi M, et al. Cost-effectiveness of biologics for severe asthma. Ann Allergy
Asthma Immunol. 2019;123(2):127-133.
21. Mortimer K, et al. Home environmental interventions for asthma. Cochrane
Database Syst Rev. 2010;(1):CD006283.
22. Ryan D, et al. The role of digital health in asthma management. J Allergy Clin
Immunol Pract. 2020;8(2):498-506.
